Everolimus Retroaldol Degradation Product

(S)-(2R,3S,6R,E)-1-((1S,3R,4R)-4-(2-Hydroxyethoxy)-3-methoxycyclohexyl)-2,6,8-trimethyl-5,9-dioxonon-7-en-3-yl 1-(2-((2R,3R,6S)-6-((2S,3E,5E,7E,9S,11R)-2,13-dimethoxy-3,9,11-trimethyl-12-oxotrideca-3,5,7-trien-1-yl)-2-hydroxy-3-methyltetrahydro-2H-pyran-2-yl)-2-oxoacetyl)piperidine-2-carboxylate; Everolimus Ring-opening Impurity

C[C@H](C[C@@]1([H])C[C@@H](OC)[C@H](OCCO)CC1)[C@]([H])(CC([C@H](C)/C=C(C=O)\C)=O)OC([C@H]2N(C(C([C@@]3(O)[C@H](C)CC[C@@]([H])(C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(COC)=O)O3)=O)=O)CCCC2)=O